Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Cigna Shares Hit 52-Week Low on Trump Bid to Kill ACA

Published 03/26/2019, 02:19 PM
Updated 03/26/2019, 02:40 PM
© Reuters.

Investing.com - The Trump Administration wants the entire Affordable Care Act (also known as Obamacare) declared unconstitutional and Cigna (NYSE:CI) shares fell back Tuesday as a result.

The shares were down 1.8% Tuesday afternoon and hit a 52-week low of $160.37. The shares are off 29% since peaking on Dec. 3 and down more than 15% this year.

The administration's position came in a letter sent to the Fifth Circuit Court of Appeals. The court is hearing an appeal of a Texas court decision that declared the entire ACA unconstitutional.

The administration told the appeals court that “it is not urging that any portion of the district court’s judgment be reversed,” the New York Times reported.

Health-insurance stocks generally were lower on Tuesday.

UnitedHealth Group (NYSE:UNH), off 1.6%, was the worst performer among the 30 stocks in the Dow Jones Industrial Average, and Molina Healthcare (NYSE:MOH) was off 9.5%.

Critics of the Administration's current position, who include the health-insurance industry, say gutting the ACA entirely will take away insurance coverage from as many as 100 million Americans and cause chaos for consumers, healthcare providers and health-insurance companies.

The case will likely be appealed to the Supreme Court no matter who wins on the appeal. It will also likely be a political issue for the 2020 election.

Cigna earned $2.46 a share in the fourth quarter on revenue of $14.3 billion. Both beat estimates from analysts polled by Investing.com. The stock has been weak since December in part because of the uncertainty created by the Texas ACA decision.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Cigna will be spending much of this year digesting its $67-billion acquisition pharmacy benefit manager Express Scripts (NASDAQ:ESRX).

Its 2019 results won't be comparable to 2018 because the Express Scripts deal. The current Investing.com consensus is earnings of $3.76 a share on revenue of $34.1 billion.

The Express Scripts deal is part of an industry trend for health insurers and pharmacy management operations to combine in hopes of cutting prices. But the deals will also intensify competition. United Health, which owns Optum Rx and drugstore chain CVS Health (NYSE:CVS)) bought Aetna (NYSE:AET) in a $70 billion deal in late 2018.

Latest comments

The thieves are the Insurance Cos and Pharmacy benefit Managers and let us not forget the crooked hospitals
People are going to get sick, insured or not. So what happens to the costs of those 100 Million people who would no longer have insurance? 2 things happen. The hospital raises prices for the ones that do pay to cover the ones that don't and the tax payer eats the rest in hospital write offs. YOU WILL PAY MORE if Trump gets this through. Trump has to make cuts to get his budget passed. So millions of Americans are going to lose their health care coverage for his pew pew star wars plan (and we aren't even at war with anybody). How is this logical?
There shouldn't be any insurance.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.